Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDINALS
2023-510317-26-00Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Utreloxastat (PTC857) arm with Placebo arm (2 arms). Started Apr 2024; status: completed.
02
Drugs
utreloxastat
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2023-510317-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510317-26-00.